The briefing
New research from the USC Schaeffer Center, published in the American Journal of Managed Care, shows a sharp rise in Medicare prescriptions for Wegovy after coverage expanded to cardiovascular risk reduction. Despite the increase, only a fraction of eligible beneficiaries received the treatment.
Original headline
Medicare prescriptions for Wegovy jumped after approval for heart disease